Immunoassay AnalyzersModern immunoassay systems are designed to perform a wide range of clinical tests and help detect several diseases. They are used to test for cancer markers, infectious diseases, cardiac analysis, therapeutic drug monitoring, and for allergy testing. Immunoassay analyzers use two methods to process a sample – random sampling and continuous access sampling.

According to a recently published research report from Markets and Markets, the global immunoassay market is expected to reach $23,712.4 million in 2020 from $14,926.3 million in 2014, at a CAGR of 9.7%. The reagents and kits segment accounted for the largest share of the market in 2014 and is expected to grow at the highest CAGR during the forecast period.

The report segmented the immunoassay market on the basis of technology, products and services, applications, end users, and regions. Factors contributing to the growth in demand for immunoassay testing are:

  • Rising incidence of chronic diseases
  • Rising aging population
  • Increase in variety of reagents and analytical techniques used
  • High growth of at-home testing market

The report identified the key players in the market as Roche Diagnostics (Switzerland), Siemens Healthcare (Germany), Abbott Laboratories (U.S.), Beckman Coulter (U.S.), Ortho Clinical Diagnostics (U.S.), and bioMérieux (France). Based on region, North America accounted for the largest share of the market in 2014, while Asia is expected to witness the highest growth rate.

Today’s immunoassay analyzers are powerful and efficient and can meet the demands of large volume testing laboratories. They can conduct several tests per hour and come with features such as touch screen interface, easy-to-use software and ready-to-use reagents. These instruments ensure benefits such as easy and trouble free operation, workflow flexibility, fast turnaround times, broad measuring ranges, and more. The future will most likely involve the development of more sensitive assays and even more superior technology for the discovery of new biomarkers for disease diagnosis.